Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-03-28 00:00:00 ET · period of report 2022-03-24 · accession 0001209191-22-021393 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-28 | 2022-03-24 | DFTX | Hu Cynthia W. | CLO, Sec | A - Grant | $0.00 | +1.20M | 1.20M | New | $0 |
| D | 2022-03-28 | 2022-03-24 | DFTX | Hu Cynthia W. | CLO, Sec | A - Grant | $0.00 | +1.56M | 1.56M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Subordinate Voting Shares | 2022-03-24 | A | A | 1,200,000 | $0.00 | 1,200,000 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 25% shall vest on December 6, 2022, with 1/48th vesting at the end of each month thereafter for the succeeding 36 months, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-24 | A | A | 1,560,000 | $0.00 | 1,560,000 | D | $1.18 · — to 2027-03-23 | 1,560,000 Subordinate Voting Shares | (F2) The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. (F3) 25% of the shares underlying the option shall vest and become exercisable on December 6, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/48th of the total shares vesting at the end of each month thereafter for the succeeding 36 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. |